US EditionPublished • loading... • Updated
Ozempic in a Pill? Clinical Trial Finds Oral Semaglutide Works For Weight Loss
Orforglipron demonstrated an average 11% body weight loss and improved blood sugar control over oral semaglutide, potentially expanding access to effective diabetes and obesity treatments.
- On Wednesday, researchers announced final clinical trial results published in The New England Journal of Medicine showed orforglipron produced significant weight loss, and Eli Lilly and Company plans FDA submission later this year.
- Because pills deliver less drug than injections, oral GLP-1 agents may improve access and reduce costs, especially since they don't require refrigeration or cost more than $1,000 monthly.
- In the large multi-country trial, more than 3,100 patients from nine countries tested three doses over about a year and a half, with an average 11% weight loss at the 36 mg dose and about 7% stopping due to gastrointestinal side effects.
- In direct comparisons, orforglipron outperformed an oral semaglutide tablet for blood-sugar control and weight loss, with the highest dose helping nearly three times as many participants reach near-normal A1C.
- As rivals race, Novo Nordisk reported an oral semaglutide enabling more than 13% weight loss and began production to ensure ample supply amid competition with Eli Lilly and Company.
Insights by Ground AI
20 Articles
20 Articles
Researchers show that this drug taken orally can reduce body weight by up to 11% This is the little-known fruit of Cadiz that has Chinese origin and that many confuse with small apples
Coverage Details
Total News Sources20
Leaning Left4Leaning Right3Center3Last UpdatedBias Distribution40% Left
Bias Distribution
- 40% of the sources lean Left
40% Left
L 40%
C 30%
R 30%
Factuality
To view factuality data please Upgrade to Premium
